OUTLOOK THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.66% for the 12-month period ending 2020-09-30, per its 10-K filed 2020-12-23.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2020-12-23
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-12-31 was 3.02%, a 40.47% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-12-31 was 2.15%.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.66%, a 67.33% decline from fiscal 2019.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.02%, a 27.86% decline from fiscal 2018.
- OUTLOOK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.80%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2020-09-30 | 0.66% 10-K · filed 2020-12-23 | |||
| 2019-09-30 | 2.02% 10-K · filed 2020-12-23 | |||
| 2019-06-30 | 2.46% 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | 2.79% 10-Q · filed 2019-05-15 | |||
| 2018-12-31 | 3.02% 10-Q · filed 2019-02-14 | |||
| 2018-09-30 | 2.80% 10-K · filed 2019-12-19 | |||
| 2018-06-30 | 2.72% 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | 2.25% 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | 2.15% 10-Q · filed 2018-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |